Encapsulated cell therapy for macular telangiectasia advancing
n this Healio Video Perspective from OIS Retina, Richard Small previews a presentation that will cover phase 3 data on encapsulated cell therapy for the treatment of macular telangiectasia.
Two studies demonstrated statistical and clinical efficacy for the treatment of MacTel over 2 years, “but we also have data which actually shows that our technology and platform last much longer than 2 years,” he said.
The NT-501 implant demonstrated positive results in two replicative phase 3 clinical trials for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
Neurotech is preparing a license application for the FDA with the goal of having the platform on the market in 2024.
The investigational encapsulated cell therapy is designed to produce ciliary neurotropic factor continuously, thus changing the rate of disease progression in patients with macular telangiectasia type 2.
NT-501 was well tolerated by patients and demonstrated a 56.4% rate of reduction in disease progression in Protocol A (P < .0001) and a 29.2% rate of reduction in Protocol B (P = .021). These are the first phase 3 clinical results to demonstrate preservation of photoreceptors with a novel ophthalmic neuroprotectant therapy, according to the release.
“These findings are an important step towards giving hope to those currently suffering with unrelenting vision loss and who don’t have a way of stopping the progression of the disease today. We look forward to engaging with the FDA throughout the review process,” Richard Small, CEO of Neurotech, said in the release.
ارسال به دوستان